Bolsa ES - Gráfico y Resumen de Bristol-Myers Squ [BMY]

Bristol-Myers Squ - [Ticker: BMY]
Última Transacción	32,520	Hora de Cotización	2012-05-23 - 21:00
Variación	-0,310 (-0.94%)	Rango 52 Semanas	[25,690 - 35,440]
Máximo	32,860	Mínimo	32,360
Volumen	7.728.586	Volumen Medio (3m)	9.583.630
Demanda / Oferta	N/A	Yield	4,08
Cierre Anterior	32,830	PER	14,73%
Apertura	32,740	EPS	2,23
Fecha Ex-Dividendo	2012-05-24	Fecha Dividendo	2012-05-24
Capitalización Bursátil	55	Objetivo Estimado 1 Año	34,390
Nota: Los datos pueden tener un retraso de algunos minutos.

Ver cotizaciones de otros activos

Intradía 5 días 1 mes 3 meses 6 meses 1 año 2 años 5 años 10 años Utilice este gráfico en su sitio web!
Gráfico de Bristol-Myers Squ - [Ticker: BMY]

Cambiar para Gráfico Interactivo de Análisis Técnico de Bristol-Myers Squ

Últimos 10 Tópicos en el Foro relacionados con Bristol-Myers Squ:

No se han encontrado tópicos relacionados con Bristol-Myers Squ [BMY], pero se aconseja la búsqueda en el Foro para tópicos relacionados con Bristol-Myers Squ.

Noticias de Bristol-Myers Squ [BMY]: (ordenadas por relevancia)

The Zacks Analyst Blog Highlights: Mylan, Bristol-Myers Squibb, Sanofi, Teva ...
Sacramento Bee
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Mylan, Inc. (Nasdaq:MYL), Bristol-Myers Squibb Co. (NYSE:BMY), Sanofi (NYSE:SNY), ...
Generic Launches Continue At MylanDaily Markets

los 28 artículos informativos »

Institutional Trading Activity Report for Bristol-Myers Squibb Company (BMY)
AVAFIN
Bristol-Myers Squibb Company is trading below the 50 day moving average and higher than the 200 day moving average. Shares of BMY opened today at $32.68 and settled the day up $0.12 to $32.83 during the session. The day's trading range is between ...

Bristol-Myers Squibb's Thud Heard Round the World
DailyFinance
By Sean Williams, The Motley Fool It was only a matter of time before Plavix, Bristol-Myers Squibb's (NYS: BMY) best-selling blood-clot-fighting drug, was set to lose patent protection. Well, folks, that day has come and gone as of last Thursday, ...
BMO Capital Markets Analysts Begin Coverage on Bristol Myers Squibb (BMY)Movie News Guide (blog)
Generic Launches Continue at Mylan - AnalystBlog - In SpotlightThe Mumbai Times

los 6 artículos informativos »

Are 3 Failed Phase 3 Trials Enough?
DailyFinance
Sorafenib is the generic name for Nexavar, and carboplatin and paclitaxel are generic versions of drugs from Bristol-Myers Squibb (NYS: BMY) . But a subset of patients with squamous cell cancer, a subtype of lung cancer, fared worse, giving Onyx and ...

y más »

Dividend.com

Our Take: Bristol Myers Squibb Started as ?Outperform? at BMO Capital (BMY)
The Mumbai Times
Pharmaceuticals giant Bristol Myers Squibb Co. (BMY) on Friday caught some bullish commentary from analysts at BMO Capital. The firm initiated coverage on BMY with an ?Outperform? rating and $39 price target, which suggests a 19% upside to the stock's ...
Bristol-Myers anticipates significant decline in US clopidogrel sales as ...The Pharma Letter
Bristol-Myers starts Orencia manufacturing at new plantFiercePharma Manufacturing
Bristol-Myers (BMY) Announces FDA Approval of Devens, MA Plant for Manufacture ...StreetInsider.com (subscription)
EON: Enhanced Online News (press release) -AVAFIN -MedCity News
los 24 artículos informativos »

Asian Scientist Magazine

Manufacturing Facility Cleared at BMY
Zacks.com
Bristol-Myers Squibb Company (BMY - Analyst Report) received some encouraging news when the US Food and Drug Administration (FDA) cleared a biologics manufacturing facility of the company for producing its rheumatoid arthritis (RA) drug, Orencia.
Bristol-Myers Squibb and Tsinghua University Enter Strategic PartnershipMarketWatch (press release)
Bristol-Myers Squibb to Present New Data on ORENCIA(R) (abatacept) at the ...Sacramento Bee
Bristol-Myers Squibb to Present New Data on ORENCIA® (abatacept) at the ...SunHerald.com

los 97 artículos informativos »

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers ...
Zacks.com
Stocks recently featured in the blog include Dr. Reddy's Laboratories (RDY - Snapshot Report), Bristol-Myers Squibb & Co. (BMY - Analyst Report), Teva Pharmaceutical Industries Ltd. (TEVA - Analyst Report), Biogen Idec (BIIB - Analyst Report) and Elan ...

y más »

U.S. News & World Report

New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 ...
MarketWatch (press release)
Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on its approved and investigational oncology compounds will be featured in ten oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in ...
Drug Makers Continue Shift To Targeted Cancer TherapiesWall Street Journal
ASCO '12 Abstract Dump: Cancer Stocks in FocusTheStreet.com
Highlights of presentations planned for ASCO meetingThe Pharma Letter

los 126 artículos informativos »

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers ...
Sacramento Bee
Stocks recently featured in the blog include Dr. Reddy's Laboratories (NYSE:RDY), Bristol-Myers Squibb & Co. (NYSE:BMY), Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA), Biogen Idec (Nasdaq:BIIB) and Elan Corporation, plc (NYSE:ELN).

y más »

Lilly, Jaguar Land Rover, Viacom: Intellectual Property
BusinessWeek
(LLY) (LLY) and AstraZeneca Plc (AZN) won't have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY) (BMY)'s Plavix after the drug lost US patent protection yesterday.
Plavix Patent Loss Doesn't Mean Gain by Competing Blood ThinnersBloomberg

los 4 artículos informativos »

The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Bristol-Myers ...
PR Newswire (press release)
Stocks recently featured in the blog include Dr. Reddy's Laboratories (NYSE: RDY), Bristol-Myers Squibb & Co. (NYSE: BMY), Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), Biogen Idec (Nasdaq: BIIB) and Elan Corporation, plc (NYSE: ELN).

y más »

Lilly, Jaguar Land Rover, Viacom: Intellectual Property
Bloomberg
(LLY) and AstraZeneca Plc (AZN) won't have an easier time gaining more of the market for blood thinners dominated by Bristol-Myers Squibb Co. (BMY)'s Plavix after the drug lost US patent protection yesterday. Lilly's Effient and AstraZeneca's Brilinta ...

y más »

Dividend.com

Bristol-Myers Profit Climbs, Backs Forecast
NASDAQ
(RTTNews.com) - Bristol-Myers Squibb Co. (BMY) reported Thursday a 12 percent increase in first-quarter profit, above Street estimates, boosted by higher sales, even as its blockbuster drug Plavix recorded lower sales. The Biopharmaceutical firm also ...
Bristol Myers Squibb Co (NYSE:BMY) Meets Analysts Forecasts; investors Focus ...PT News
Bristol Myers Squibb Co. (NYSE:BMY) Shares Down As Revenue Misses ForecastU.S. Election News
Bristol-Myers Squibb Invites Public To Listen To Webcast Of 2012 Annual MeetingTheStreet.com (press release)
The Pharma Letter
los 95 artículos informativos »

Pfizer (NYSE:PFE) Cancers Drug Xalkori Stops Deadly Kids Tumor ?PFE, MRK, ABT ...
The Mumbai Times
Merck & Co., Inc. (NYSE:MRK) decreased -0.55% to settle at $37.82, Abbott Laboratories (NYSE:ABT) fell -1.06% to end at $61.57 while Bristol Myers Squibb Co. (NYSE:BMY) moved down -0.09% to finish on Friday at $32.72. Pfizer Inc. (NYSE:PFE) began the ...
Healthcare Giant Pfizer (NYSE:PFE) Recalls 650000 Units of Advil Liqui-Gels ...eStocksDaily
Pfizer Inc. (NYSE:PFE) Engages Distributors To Recall Advil Liqui-Gels From StoresU.S. Election News

los 5 artículos informativos »

WWLP 22News

FDA Panel Votes Against Expanded Approval Of Bayer, J&J's Xarelto
NASDAQ
Another blood-thinning drug, Eliquis by Bristol-Myers Squibb Co. (BMY) and Pfizer Inc. (PFE) is approved for short-term use in Europe. The companies are hoping for FDA approval to market Eliquis as a stroke-prevention treatment in atrial-fibrillation ...
J&J-Bayer Xarelto's Use in Prevention Is Effective, FDA SaysBusinessWeek
Johnson & Johnson's Xarelto Should Be Given to More Patients, FDA Staff SaysMinyanville.com
FDA review backs Xarelto for big new use in ACS patientsFiercePharma
FierceBiotech
los 286 artículos informativos »

Para más noticias de Bristol-Myers Squ hacer clic aquí:
Noticias de Bristol-Myers Squ